A217 Erythropoiesis-Stimulating Agents: No Impact on Long-Term Outcome in MM Patients in the VISTA Trial

PG Richardson; K Liu; William Deraedt; Helgi van de Velde; Rudolf Schlag; N Khuageva; Meletios A Dimopoulos; O Shpilberg; Martin Kropff; Michel Delforge; Maria Teresa Petrucci; Viktor Rossiev; Jie Hou; Tadeusz Robak; MV Mateos; KC Anderson; Andrew Cakana; Jesús F. San Miguel

doi:10.1016/s1557-9190(11)70505-4

Related publications

Article2008

Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.

Paul G. Richardson, Rudolf Schlag, Nuriet K. Khuageva, Meletios A Dimopoulos, Ofer Shpilberg, Martin Kropff, Michel Delforge, Maria Teresa Petrucci, Victor Rossiev, Jian Hou, Tadeusz Robak, María‐Victoria Mateos, Kenneth C. Anderson, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesús F. San Miguel

Article2012

The Use of Erythropoiesis-Stimulating Agents in the Intensive Care Unit

Michaël Piagnerelli, Jean Louis Vincent

Article2003

Long-term outcome in ICU patients:

Francisca García Lizana, Daliana Peres Bota, Michaël De Cubber, Jean Louis Vincent

Article2009

Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma

Eirini Katodritou, Meletios A Dimopoulos, Konstantinos Zervas, Evangelos Terpos

Article2009

VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study

Meletios A Dimopoulos, PG Richardson, Rudolf Schlag, N Khuageva, Ofer Shpilberg, Efstathios Kastritis, Martin Kropff, MT Petrucci, Michel Delforge, Julia Alexeeva, Henri Schots, Tamás Masszi, MV Mateos, William Deraedt, KeXin Liu, Andrew Cakana, Ann Van de Velde, Jesús F. San Miguel